WEST CHESTER, PA — Molecular Targeting Technologies Inc. (MTTI) will present clinical data from 81 patients at the 5th Targeted Radiopharmaceuticals Summit, offering evidence that its Evans Blue drug delivery …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.